Skip to content

GLP-1 weight loss results, from the FDA labels

Average change in body weight in the trials each label reports, next to placebo. Every trial had its own people, length and design, so compare within a trial, not across medications.

Zepbound injection

Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight dailymed.nlm.nih.gov
Study 1
Placebo-3.1%
5 mg-15.0%
10 mg-19.5%
15 mg-20.9%
Study 2
Placebo-3.2%
10 mg-12.8%
15 mg-14.7%

Average % change in body weight. Arms: dailymed.nlm.nih.gov Results: dailymed.nlm.nih.gov

  • Study 1 design (72 weeks, adults without type 2 diabetes). Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI ≥30 kg/m2), or with overweight (BMI 27 to <30 kg/m2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded.dailymed.nlm.nih.gov, Sep 27, 2026
Difference from placebo, and share who lost at least 5%
  • Difference from placebo (95% CI). % Difference from placebob (95% CI) -11.9 (-13.4, -10.4)d -16.4 (-17.9, -14.8)d -17.8 (-19.3, -16.3)d -9.6 (-11.1, -8.1)d -11.6 (-13.0, -10.1)ddailymed.nlm.nih.gov, Sep 27, 2026
  • % of patients losing >=5% body weight. % of Patients losing ≥5% body weight 34.5 85.1 88.9 90.9 32.5 79.2 82.8dailymed.nlm.nih.gov, Sep 27, 2026

Wegovy injection

Table 8. Changes in Body Weight at Week 68 in Studies 2, 3, and 4 with WEGOVY 2.4 mg Injection dailymed.nlm.nih.gov
Study 2
Placebo-2.4%
injection-14.9%
Study 3
Placebo-3.4%
injection-9.6%
Study 4
Placebo-5.7%
injection-16%

Average % change in body weight. Arms: dailymed.nlm.nih.gov Results: dailymed.nlm.nih.gov

Table 8. Changes in Body Weight at Week 68 in Studies 2, 3, and 4 with WEGOVY 2.4 mg Injection dailymed.nlm.nih.gov
Trial 1
Placebo-3.9%
2.4 mg-15.5%
7.2 mg-18.8%
Trial 2
Placebo-3.8%
2.4 mg-10.4%
7.2 mg-13.2%

Average % change in body weight. Arms: dailymed.nlm.nih.gov Results: dailymed.nlm.nih.gov

  • Study 2 design (68 weeks, adults without type 2 diabetes). Study 2 was a 68-week trial that enrolled 1,961 patients with obesity (BMI greater than or equal to 30 kg/m2) or with overweight (BMI 27 to 29.9 kg/m2) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded.dailymed.nlm.nih.gov, Sep 27, 2026
Difference from placebo, and share who lost at least 5%
  • Difference from placebo (95% CI). % difference from placebo (LSMean) (95% CI) -12.4 (‑13.3; ‑11.6)* -6.2 (-7.3; -5.2)* -10.3 (-11.8; -8.7)*dailymed.nlm.nih.gov, Sep 27, 2026
  • 7.2 mg difference from 2.4 mg (Study 8). Difference (%) from 2.4 mg [95% CI] -3.3 [-4.9; -1.6]*dailymed.nlm.nih.gov, Sep 27, 2026

Wegovy tablets

Table 11. Changes in Body Weight at Week 64 in Study 7 with WEGOVY 25 mg Tablets dailymed.nlm.nih.gov
Study 7
Placebo-2.4%
25 mg tablet-13.6%

Average % change in body weight. Arms: dailymed.nlm.nih.gov Results: dailymed.nlm.nih.gov

  • Study 7 design (64 weeks, 25 mg tablets, no type 2 diabetes). Study 7 was a 64-week trial that enrolled 307 patients with obesity (BMI greater than or equal to 30 kg/m2) or with overweight (BMI 27-29.9 kg/m2) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded.dailymed.nlm.nih.gov, Sep 27, 2026
  • Tablets not studied for weight reduction in type 2 diabetes. WEGOVY tablets have not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight [see Clinical Studies (14.2)].dailymed.nlm.nih.gov, Sep 27, 2026
Difference from placebo, and share who lost at least 5%
  • Difference from placebo (95% CI). % difference from placebo (LSMean) (95% CI)3 -11.2 [-13.6; -8.8]2dailymed.nlm.nih.gov, Sep 27, 2026

Foundayo tablets

Table 6: Changes from Baseline in Body Weight at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition dailymed.nlm.nih.gov
Trial 1
Placebo-2.1%
5.5 mg-7.4%
9 mg-8.3%
17.2 mg-11.1%
Trial 2
Placebo-2.5%
5.5 mg-5.1%
9 mg-7%
17.2 mg-9.6%

Average % change in body weight. Arms: dailymed.nlm.nih.gov Results: dailymed.nlm.nih.gov

  • Efficacy trials used an investigational formulation, presented as equivalent Foundayo doses. based on adequate and well-controlled trials of an investigational orforglipron formulation (Trials 1 and 2), referred to in this section as FOUNDAYO.dailymed.nlm.nih.gov, Sep 27, 2026
  • Trial 1 design (72 weeks, adults without type 2 diabetes). Trial 1 (NCT05869903) was a 72-week trial that enrolled 3,127 adult patients with obesity (BMI ≥30 kg/m2), or with overweight (BMI 27 to <30 kg/m2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease; patients with type 2 diabetes were excluded.dailymed.nlm.nih.gov, Sep 27, 2026
Difference from placebo, and share who lost at least 5%
  • Difference from placebo (95% CI). % difference from placebo (95% CI)b -5.3 (-6.1, -4.4)c -6.2 (-7.1, -5.3)c -9 (-10, -8.1)c -2.6 (-3.5, -1.6)c -4.5 (-5.4, -3.6)c -7.1 (-8.1, -6.1)cdailymed.nlm.nih.gov, Sep 27, 2026
  • % of patients losing >=5% body weight. % of patients who lost ≥5% body weight 26.8 59.6 63.1 71.5 26.8 47.4 54.7 67dailymed.nlm.nih.gov, Sep 27, 2026

Ozempic and Mounjaro are labeled for type 2 diabetes, so their labels do not report weight-management results. Prices: GLP-1 without insurance. This page reports the labels; it is not medical advice. Medical disclaimer.